-

Verily Health Secures New Investment From NVIDIA and CU Healthcare Innovation Fund

Investment supports the next phase of Verily’s precision health AI strategy

DALLAS--(BUSINESS WIRE)--Verily Health Inc. today announced it has received investment support from NVIDIA, as Verily extends its March fundraising. Existing investor CU Healthcare Innovation Fund II, LP is also making an additional investment. Verily’s current investors include Alphabet, Series X Capital, UCHealth, and others.

"We are pleased to welcome NVIDIA as a new investor in Verily. These investments strengthen our ability to pursue the opportunity ahead. Together, these investments and the continued support of our current investors accelerate our vision to build a trusted foundation for healthcare, bringing together the information and intelligence needed to power better decisions and unlock the full potential of AI across the healthcare ecosystem,” said Stephen Gillett, Chairman and CEO of Verily.

The new backing arrives as Verily scales adoption of the Verily Pre Platform, the company's flagship data and AI platform, which helps healthcare organizations make their data AI-ready and deploy AI responsibly across research and care. It also supports the growth of Verily Me, the company's patient engagement offering, extending Verily’s capabilities to support individuals throughout their healthcare journey.

Verily and NVIDIA previously announced a collaboration in October 2025. Researchers using the Verily Pre Platform will be able to leverage NVIDIA AI libraries and frameworks, including NeMo, Parabricks, RAPIDS, and NVIDIA B200 GPUs. Verily developed Forecast 1.0™, a foundation model that integrates genomics and EHR data to deliver improvements in the accuracy of predicting long-term health risks, in collaboration with NVIDIA. Leveraging the NVIDIA AI stack, the model achieved improved predictive performance and computational efficiency.

About Verily Health Inc.

Verily is a data platform and technology company purpose-built to power AI-enabled precision health solutions that accelerate research and improve care for individuals and communities. Uniquely positioned at the intersection of technology, data science, and healthcare, Verily transforms multimodal health data into insights, models, and actions that make healthcare more personalized, predictive, and precise. For more information about Verily please visit: verily.com.

Contacts

Media Contact: Laurie Ferguson, VP Communications verily-press@verily.com

Verily Health Inc.


Release Versions

Contacts

Media Contact: Laurie Ferguson, VP Communications verily-press@verily.com

More News From Verily Health Inc.

Verily Health and Autoimmune Registry Partner to Build Cross-Disease Research Infrastructure for Autoimmune Conditions

DALLAS--(BUSINESS WIRE)--Verily Health Inc., a healthcare data intelligence company, today announced a strategic partnership with Autoimmune Registry Inc. (ARI), a nonprofit nominated for the inaugural 2026 Prix Galien Patient First Award in Honor of Michael J. Fox for its work studying autoimmune diseases, the populations they affect, and how they co-occur and progress over time. Through the partnership, Verily Health will provide the patient engagement, research infrastructure, and analytics n...

Verily Health Awarded Centers for Disease Control and Prevention Contract to Support National Infectious Disease Wastewater Surveillance

DALLAS--(BUSINESS WIRE)--Verily Health Inc., a healthcare data intelligence company, announced today that it has been awarded a contract by the Centers for Disease Control and Prevention (CDC) to continue supporting the national wastewater-based infectious disease surveillance program, building on the work that the company has performed for the CDC since 2023. Under the new award, Verily Health will support CDC's National Wastewater Surveillance System through Verily Sightline, combining wastew...

Verily Health Selected to Build Data Platform for ARPA-H CIRCLE Program

DALLAS--(BUSINESS WIRE)--Verily Health Inc., a precision health AI company, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to serve as an Acceleration Platform performer for the agency's Critical Illness Immunological Reprogramming and Control Point Learning Engine (CIRCLE) program. In this role, Verily Health will build and operate the shared program database that CIRCLE's res...
Back to Newsroom